OpenBilldrug price receipt

NADAC week of 2026-10-14

PIOGLITAZONE-METFORMIN 15-850

For 30 tablets

Pharmacies pay

$7.17 filed

30 × $0.23908 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$18.31 filed

30 × $0.61035 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

2.6× estimated

Medicare paid 2.6× what pharmacies pay.

Part D averages every strength and form sold under “Pioglitazone-Metformin” / “Pioglitazone HCl/Metformin HCl” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$13.25 estimated

$7.17 + $1.08 (15%) + $5.00 fee per fill = $13.25

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

PIOGLITAZONE-METFORMIN 15-850 is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “pioglitazone hydrochloride and metformin hydrochloride” and “pioglitazone and metformin hydrochloride”, as its NDCs’ listings variously write the nonproprietary name.

FDA gives its dosage form as “tablet” and “tablet, film coated” and its route as oral.

Its labelers, the companies named on the label, are Macleods Pharmaceuticals Limited, Rising Pharma Holdings, Inc. and Aurobindo Pharma Limited.

FDA lists it under 4 Established Pharmacologic Classes: Biguanide, Peroxisome Proliferator Receptor alpha Agonist, Peroxisome Proliferator Receptor gamma Agonist and Thiazolidinedione.

The NADAC file of 2026-10-14 prices it under 5 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $7.17 for 30 tablets (30 × $0.23908 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

All 5 NDCs

Other strengths, forms and brands

1 other product in the NADAC file shares an FDA nonproprietary name with PIOGLITAZONE-METFORMIN 15-850.

ProductPharmacies pay per unitMedicare per unit
PIOGLITAZONE-METFORMIN 15-500
generic · tablet / tablet, film coated
$0.2835 per EA filed
eff. 2026-09-23
$0.61035 per EA filed
Part D 2024 average
PIOGLITAZONE-METFORMIN 15-850 this page
generic · tablet / tablet, film coated
$0.23908 per EA filed
eff. 2026-09-23
$0.61035 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 5 NDCs’ NADAC prices is $0.23908 per EA filed.

Of the 71 other products in FDA’s Biguanide class priced per EA, 61 have a higher middle NADAC price and 10 a lower one. The one in the middle is SYNJARDY XR 5-1,000 MG TABLET, at $5.61111 per EA filed (eff. 2026-09-23).

Of the 23 other products in FDA’s Peroxisome Proliferator Receptor alpha Agonist class priced per EA, 11 have a higher middle NADAC price and 12 a lower one. The one in the middle is FENOFIBRATE 200 MG CAPSULE, at $0.16437 per EA filed (eff. 2026-09-23).

Of the 7 other products in FDA’s Peroxisome Proliferator Receptor gamma Agonist class priced per EA, 4 have a higher middle NADAC price and 3 a lower one. The one in the middle is PIOGLITAZONE-METFORMIN 15-500, at $0.2835 per EA filed (eff. 2026-09-23).

Of the 7 other products in FDA’s Thiazolidinedione class priced per EA, 4 have a higher middle NADAC price and 3 a lower one. The one in the middle is PIOGLITAZONE-METFORMIN 15-500, at $0.2835 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $18.31 for 30 tablets, at an average of $0.61035 per EA in 2024 (2024-01-01 to 2024-12-31) for “Pioglitazone-Metformin” and “Pioglitazone HCl/Metformin HCl”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 48,576 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for PIOGLITAZONE-METFORMIN 15-850 labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Pioglitazone-Metformin / Pioglitazone HCl/Metformin HCl: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.